Overview

HIV Risk Reduction and Drug Abuse Treatment in Iran

Status:
Withdrawn
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
A randomized, double blind clinical trial comparing buprenorphine and naltrexone maintenance treatment when combined with drug abuse and HIV risk reduction counseling (DC-HIV) for heroin and opium addicts in Iran.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Buprenorphine
Naltrexone